^
Association details:
| Biomarker: | EGFR L747P |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
Published date:
03/15/2022
Excerpt:
An 84-year-old white male with remote smoking history presented with bilateral pulmonary nodules and multiple subcentimeter enhancing brain lesions 2 years after receiving stereotactic radiation therapy for a left upper lobe lung adenocarcinoma....surgical biopsy results revealed an EGFR L747P mutation…the patient was initiated on osimertinib. Treatment was well-tolerated and follow-up imaging results revealed thoracic and intracranial response to therapy, which has been sustained 6 months after treatment initiation.
DOI:
10.1016/j.jtocrr.2022.100291
Source:
Title:
A rare EGFR mutation L747P conferred therapeutic efficacy to both ge?tinib and osimertinib: A case report
Published date:
09/25/2020
Excerpt:
...we reported a patient with advanced lung adenocarcinoma harboring an EGFR L747 P who benefited from first-line treatment with gefitinib. This patient achieved stable disease (SD) and had a progression-free survival (PFS) of 18 months. After disease progression, this patient was subsequently administered osimertinib and responded, as evidenced by a significant reduction in nodular lesions.
DOI:
10.1016/j.lungcan.2020.09.017
